Inke S.A., a wholly-owned subsidiary of Neuraxpharm, is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes, mainly for use in Respiratory and Central Nervous Systems (CNS) therapies. Inke has been successfully inspected by every major global authority for a wide array of products (last US-FDA inspection was in May 2016). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation.
KEY PRODUCTS
Neuraxpharm's APIs manufacturing plant.
Market Place
